Advertisement

Topics

Companies Related to "Researchers Awarded Million Study Optimal Radioactive Drugs Prostate" [Most Relevant Company Matches] RSS

01:04 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Researchers Awarded Million Study Optimal Radioactive Drugs Prostate" found in our extensive corporate database of over 50,000 company records.

Showing "Researchers Awarded Million Study Optimal Radioactive Drugs Prostate" Companies 1–25 of 5,400+

Relevant

Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 researchers at nearly 200 institutions wor...


The Prostate Cancer Foundation

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer at every stage of diagnosis. Founded in 1993, the PCF has raised more than $370 million and provided funding to more than 1,500 research projects at nearly 200 instit...

Bavarian Nordic

Bavarian Nordic initiated the development of IMVAMUNE® in 1999 and began the first clinical study in 2001. In 2003, Bavarian Nordic was awarded a contract, valued at $29 million, from the U.S. National Institutes of Health (NIH), for the further development of IMVAMUNE®. In 2004, Bavarian Nordic was awarded its second U.S. Government contract, valued at $115 million, to continue advanced devel...


Prostate Oncology Specialists, Inc.

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.

Theragenics

Theragenics Corporation is a leader in the production and sales of implantable radiation devices ("seeds") used in thetreatment of cancer. The Company produces and sells TheraSeed(R), which is a U.S. Food and Drug Administration (FDA) licensed device, based on the radioactive isotope palladium 103 (Pd-103). The Company received FDA clearanceto market TheraSeed(R) in 1986 and...

Mary Kay Foundation

The Mary Kay FoundationSM was created in 1996, and its mission is two-fold: to fund research of cancers affecting women and to help prevent domestic violence while raising awareness of the issue. By the end of 2012, The Mary Kay FoundationSM will have awarded more than $31 million to shelters and programs addressing domestic violence prevention and more th...

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.

European Randomized Study of Screening for Prostate Cancer (ERSPC)

ERSPC (European Randomized Study of Screening for Prostate Cancer)

Stratify Genomics, Inc.

Currently, there are 35,000 men annually who are unaware of a curable form of clinically significant prostate cancer. Relying solely on family history, 80% of prostate cancer cases would be missed. The most common screening tool, prostate-specific antigen (PSA) testing, has declined in usage due to controversial guidelines, which has led to a significant i...

Prostate Oncology Specialists,Inc.

Prostate Oncology Specialists is a medical group exclusively devoted to caring for men with prostate cancer. We have vast experience diagnosing and treating prostate cancer because 100% of our time is focused on managing men with this disease. Our physicians are board certified in both medical oncology and internal medicine and have made significant contributions to the scientific advancement in t...

GammaWest Brachytherapy

Brachytherapy is an advanced cancer treatment. The word "brachy" is Greek for "close by" and refers to placing radioactive seeds or sources directly in the tumor. This procedure gives physicians and patients the important advantage of applying a higher dose of radiation directly to the tumor while sparing healthy tissue and surrounding organs. Brachytherapy is a localized, precise, radiation treat...

VIRalliance

VIRalliance develops and markets high added value services and products to help optimise drug discovery and patient treatment in the fields of infectious diseases and oncology.VIRalliance has a development portfolio of innovative predictive tests to aid the optimal treatment.PHENOSCRIPT™ is the first of these tests to be made available to the public. PHENOSCRIPT™ is a novel and rapid HIV phen...

Development Specialists, Inc.

DSI’s outstanding service was awarded in the “Reorganization of the Year (Middle Market);” "Consumer and Retail Products (Over $50 Million) Sale of the Year;” and “Real Estate Deal of the Year (Under $500 Million)" categories.

Compumedics USA, Inc.

Compumedics Limited, was founded in 1987 by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major a...

Biomolex

Biomolex offers a unique microarray reader supporting new and uique methods for functional genomics and proteomics. The new method uses radioactive isotopes, rather than the traditional fluorophores for labeling of the target genes/proteins. The new technology supports simultaneous use of multiple isotope labels, which means that in each experiment cells of various origins can be labeled with diff...

Trimeris

Based in Morrisville, North Carolina, Trimeris was founded in 1993 by leading researchers in the study of the human immunodeficiency virus (HIV). Their work in the early 1990s led to a breakthrough in the fight against AIDS — an entirely new class of anti-HIV drugs called fusion inhibitors. In this section, you will find more information about our history, as well as the Trimeris mission, our le...

GenVault

GenVault provides integrated archiving and retrieval solutions for organizations managing DNA collections. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. Current State of Biosample ManagementWith the genomics revolution and the promise of genetics based medicine, both the importance and need to store biological samples have grown considerably. Researche...

Kronos Optimal Health Company

Kronos Optimal Health Company is a leader in the science of healthy living. Our programs and services have been developed by leading physicians and researchers at Kronos Science Laboratories to address a full range of life issues, from everyday fatigue to cardiovascular disease. Through our advanced clinical research and state-of-the-art medical testing, Kronos can help identify and reduce the ris...

Minomic International Ltd

Minomic International Ltd is an Australian immuno-oncology company specialising in therapeutics and diagnostics for prostate cancer and other cancers. Minomic has developed the in vitro diagnostic test called MiCheck® for the early detection of prostate cancer. Minomic is preparing to globally launch its first product, a novel prostate cancer blood test...

Rad Source Technologies, Inc.

Rad Source Technologies, Inc. develops and produces non-radioactive source irradiation equipment. We strive to expand the use of safe irradiation products by extending the abilities of non-isotope based technology as a way of replacing existing radioactive isotope equipment and making new applications practical. Irradiation itself, whether from radioisotopes or non-radioactive sources such as x-ra...

Glactone Pharma AB

Glactone Pharma AB is developing a drug for the treatment of castration resistant prostate cancer. Research has shown that the natural product galiellalactone can modulate a signaling protein (STAT3) that is over activated in cancer cells. The goal is to develop drugs against metastasizing cancer where galiellalactone is used as a chemical starting point to make new novel, patentable compounds. ...

ImmunSYS, Inc.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other adenocarcinomas. The company’s platform technology, YourVaccx™ utilizes a novel combination of the proprietary ANTIGENerator™ energ...

Nanodisc, Inc.

Nanodisc, Inc. owns an exclusive, world-wide commercial license to all applications of Nanodiscs™ – nano scale, discoidal structures composed of specially engineered proteins and phospholipid bilayers. “Nanodiscs™ were discovered and developed by Dr. Sligar, Company Co-Founder, Professor at University of Illinois at Urbana Champaign and a principal investigator in the fede...

ADAPTOGEN" INTERREGIONAL CENTER

According to the program of development and production of drugs in soft gelatin capsules IC "Adaptogen" will carry out urgent researches and works on development, study of composition both action of natural herbal oils and herbal oil extracts discovering interesting prospects in development of new pharmaceutical preparations and continues researches on development of fluid herbal pharmaceuticals. ...


More From BioPortfolio on "Researchers Awarded Million Study Optimal Radioactive Drugs Prostate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks